Somatic mutation of EGFR and rearrangement of ALK, proto-oncogene tyrosine protein kinase (ROS1), and proto-oncogene (RET) are supposed to be dependable biomarkers and effective drug targets for NSCLC (12, 13). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.